Literature DB >> 25927964

Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings.

Sulav Duwal1, Stefanie Winkelmann2, Christof Schütte3, Max von Kleist1.   

Abstract

An estimated 2.7 million new HIV-1 infections occurred in 2010. `Treatment-for-prevention' may strongly prevent HIV-1 transmission. The basic idea is that immediate treatment initiation rapidly decreases virus burden, which reduces the number of transmittable viruses and thereby the probability of infection. However, HIV inevitably develops drug resistance, which leads to virus rebound and nullifies the effect of `treatment-for-prevention' for the time it remains unrecognized. While timely conducted treatment changes may avert periods of viral rebound, necessary treatment options and diagnostics may be lacking in resource-constrained settings. Within this work, we provide a mathematical platform for comparing different treatment paradigms that can be applied to many medical phenomena. We use this platform to optimize two distinct approaches for the treatment of HIV-1: (i) a diagnostic-guided treatment strategy, based on infrequent and patient-specific diagnostic schedules and (ii) a pro-active strategy that allows treatment adaptation prior to diagnostic ascertainment. Both strategies are compared to current clinical protocols (standard of care and the HPTN052 protocol) in terms of patient health, economic means and reduction in HIV-1 onward transmission exemplarily for South Africa. All therapeutic strategies are assessed using a coarse-grained stochastic model of within-host HIV dynamics and pseudo-codes for solving the respective optimal control problems are provided. Our mathematical model suggests that both optimal strategies (i)-(ii) perform better than the current clinical protocols and no treatment in terms of economic means, life prolongation and reduction of HIV-transmission. The optimal diagnostic-guided strategy suggests rare diagnostics and performs similar to the optimal pro-active strategy. Our results suggest that 'treatment-for-prevention' may be further improved using either of the two analyzed treatment paradigms.

Entities:  

Mesh:

Year:  2015        PMID: 25927964      PMCID: PMC4423987          DOI: 10.1371/journal.pcbi.1004200

Source DB:  PubMed          Journal:  PLoS Comput Biol        ISSN: 1553-734X            Impact factor:   4.475


  58 in total

1.  Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.

Authors:  P R Harrigan; M Whaley; J S Montaner
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

2.  Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay.

Authors:  Narendra M Dixit; Alan S Perelson
Journal:  J Theor Biol       Date:  2004-01-07       Impact factor: 2.691

3.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

4.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Authors:  David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

5.  Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

Authors:  Charles Hicks; Martin S King; Roy M Gulick; A Clinton White; Joseph J Eron; Harold A Kessler; Constance Benson; Kathryn R King; Robert L Murphy; Scott C Brun
Journal:  AIDS       Date:  2004-03-26       Impact factor: 4.177

6.  Drug-class specific impact of antivirals on the reproductive capacity of HIV.

Authors:  Max von Kleist; Stephan Menz; Wilhelm Huisinga
Journal:  PLoS Comput Biol       Date:  2010-03-26       Impact factor: 4.475

7.  Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.

Authors:  Javier Martinez-Picado; Eugènia Negredo; Lidia Ruiz; Ayumi Shintani; Carmina R Fumaz; Carlos Zala; Pere Domingo; Josep Vilaró; Josep M Llibre; Pompeyo Viciana; Kurt Hertogs; Charles Boucher; Richard T D'Aquila; Bonaventura Clotet
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

8.  Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.

Authors:  Edwin DeJesus; Gisela Herrera; Eugenio Teofilo; Jan Gerstoft; Carlos Beltran Buendia; J David Brand; Cynthia H Brothers; Jaime Hernandez; Steve A Castillo; Tab Bonny; E Randall Lanier; Trevor R Scott
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

9.  Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.

Authors:  Edwin DeJesus; Debra McCarty; Charles F Farthing; Denise D Shortino; Beatriz Grinsztejn; Deborah A Thomas; Shannon R Schrader; Steve A Castillo; Michael G Sension; Kevin Gough; Sam J Madison
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

10.  Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy.

Authors:  Paola Paci; Rossella Carello; Massimo Bernaschi; Gianpiero D'Offizi; Filippo Castiglione
Journal:  BMC Infect Dis       Date:  2009-10-19       Impact factor: 3.090

View more
  1 in total

1.  Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.

Authors:  S Duwal; V Sunkara; M von Kleist
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-07-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.